 Home > Active Ingredient News > Antitumor Therapy > The Oncologist: Comparison of the efficacy of FTD/TPI and regorafenib in the treatment of patients with advanced colorectal cancer

The Oncologist: Comparison of the efficacy of FTD/TPI and regorafenib in the treatment of patients with advanced colorectal cancer

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

1 2 1 4

zoladex breast cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Trifluridine hydrochloride/tipiracil compound tablets (Trifluridine/Tipiracil; FTD/TPI or TAS-102) and regorafenib are both approved for the third-line treatment of recurrent/metastatic colorectal cancer
.

The phase III clinical study CORRECT confirmed that regorafenib improved the OS of patients compared with placebo (median OS, 6.

The study included eligible patients from 2012 to 2017 and compared the real-world objective response rate (rwORR), the real-world disease control rate (rwDCR), and survival
.

Compare the real-world objective response rate (rwORR), the real-world disease control rate (rwDCR), and survival

From April 2012 to December 2017, 126 patients received FTD/TPI treatment, and 95 patients received regorafenib treatment

The rwORR of FTD/TPI treatment is higher than that of regorafenib (rwORR 52.

Efficacy evaluation

The median OS of all patients treated with FTD/TPI and regorafenib were 7.
5 months (95% CI, 6.
0-8.
8) and 7.
1 months (95% CI, 5.
0-8.
2), respectively
.

In subgroup analysis, when used as second-line or third-line treatment, the median OS of the two groups was 7.

The median OS of all patients treated with FTD/TPI and regorafenib were 7.

Compared with regorafenib treatment, patients treated with FTD/TPI have a higher incidence of hematological toxicity, especially the incidence of neutropenia (IRR=5.
35; 95%CI, 2.
01-14.
21)
.

In summary, studies have shown that FTD/TPI has a better tumor response rate and disease control rate than regorafenib in the treatment of patients with advanced colorectal cancer
.

Studies have shown that FTD/TPI has a better tumor response rate and disease control rate than regorafenib in the treatment of patients with advanced colorectal cancer

Original source:

Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Ng K, Fuchs CS.

Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Ng K, Fuchs CS.
Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Oncologist.
2021 Aug 18.
doi: 10.
1002/onco.
13942.
Epub ahead of print.
PMID: 34406678.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.